Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 5Terminated 3Recruiting 2Withdrawn 1Unknown 1Available 1Approved for marketing 1Active not recruiting 1

Sponsor Class

OTHER 22NIH 8INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 429Breast Neoplasms 298Neoplasms 296Colorectal Neoplasms 242Neoplasm Metastasis 197Ovarian Neoplasms 171Lung Neoplasms 150Recurrence 147Prostatic Neoplasms 146Pancreatic Neoplasms 142Multiple Myeloma 136Stomach Neoplasms 129Squamous Cell Carcinoma of Head and Neck 128Melanoma 123Leukemia, Myeloid, Acute 115Endometrial Neoplasms 115Advanced Solid Tumors 113Advanced Solid Tumor 108Carcinoma, Hepatocellular 102Triple Negative Breast Neoplasms 101Small Cell Lung Carcinoma 88Uterine Cervical Neoplasms 86Lymphoma, Non-Hodgkin 83Carcinoma, Renal Cell 72Lymphoma, Follicular 71Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 65Solid Tumor 64Lymphoma, Large B-Cell, Diffuse 64Hematologic Neoplasms 62

Interventions

belzutifan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Pheochromocytoma × Clear all
NCT04924075 2026-05-28

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting
322 enrolled 1 FDA
CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Perspective Therapeutics

Phase 1/2 Recruiting
300 enrolled
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡